Bausch Health posts Q3 2026 earnings beat, raises full‑year guidance and launches $50 M buyback
Bausch Health reported third‑quarter 2026 revenue of $2.94 billion, up 10% on a reported basis and 8% organically. Adjusted earnings per share rose 53% to $1.77, while GAAP EPS was $1.15. The company lifted its 2026 revenue outlook to $10.975‑$11.175 billion, raised adjusted EBITDA guidance to $4.315‑$4.415 billion, announced a $50 million share repurchase program and cut net debt by $521 million.
Why it matters
The raised guidance expands the revenue and EBITDA targets investors had for the year, while the buyback and debt reduction improve balance‑sheet strength and could support the stock price, according to the company’s announcement.
Key facts
- 1Consolidated reported revenue for Q3 2026 was $2.94 billion, a 10% increase year‑over‑year. prnewswire.com
- 2Adjusted earnings per diluted share for the quarter were $1.77, a 53% rise from the prior year. prnewswire.com
- 3GAAP earnings per diluted share for the quarter were $1.15. prnewswire.com
- 4Adjusted EBITDA for Q3 2026 was $1,305 million, up 32% year‑over‑year. prnewswire.com
- 5Full‑year 2026 revenue guidance was raised to $10.975 billion‑$11.175 billion. investing.com
- 6Full‑year 2026 adjusted EBITDA guidance was raised to $4.315 billion‑$4.415 billion. investing.com
Summary written by AlphAI AI Desk from 20 of 23 sources. Not investment advice. Figures are as stated by the linked sources.